Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | MRD status after liso-cel in the TRANSCEND-CLL-004 trial

Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the MRD status of relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients after lisocabtagene maraleucel treatment in the TRANSCEND-CLL-004 trial (NCT03331198). She also discusses the next stages for the trial, which will also look at combining the agent with ibrutinib. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.